{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:17:38Z","timestamp":1791407858592,"version":"4.3.3"},"reference-count":38,"publisher":"Elsevier BV","issue":"1","content-domain":{"domain":["cancerletters.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.canlet.2013.04.012","type":"journal-article","created":{"date-parts":[[2013,4,18]],"date-time":"2013-04-18T11:05:54Z","timestamp":1366283154000},"page":"53-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1\/cip1 and by inhibiting mutant p53"],"prefix":"10.1016","volume":"336","author":[{"given":"Shelly","family":"Seward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Assaad","family":"Semaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aamer M.","family":"Qazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oksana V.","family":"Gruzdyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhar","family":"Chamala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Cameron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rouba","family":"Ali-Fehmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Bouwman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adnan R.","family":"Munkarah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald W.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh B.","family":"Batchu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2012","key":"10.1016\/j.canlet.2013.04.012_b0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2013.04.012_b0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/IGC.0b013e31823c6f80","article-title":"Survival rates for international federation of gynecology and obstetrics stage III ovarian carcinoma by cell type: a study of 262 unselected patients with uniform pathologic review","volume":"22","author":"Seidman","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2013.04.012_b0015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminoncol.2004.10.015","article-title":"Clinical update: novel targets in gynecologic malignancies","volume":"31","author":"Aghajanian","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.canlet.2013.04.012_b0020","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/nrc1991","article-title":"Polycomb silencers control cell fate, development and cancer","volume":"6","author":"Sparmann","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2013.04.012_b0025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.gde.2004.02.001","article-title":"The functions of E (Z)\/EZH2-mediated methylation of lysine 27 in histone H3","volume":"14","author":"Cao","year":"2004","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.canlet.2013.04.012_b0030","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","article-title":"EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells","volume":"100","author":"Kleer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.04.012_b0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/bjc.2011.551","article-title":"The role of EZH2 in tumour progression","volume":"106","author":"Chang","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2013.04.012_b0040","first-page":"1","article-title":"EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis","author":"Crea","year":"2012","journal-title":"Cancer Metast. Rev."},{"key":"10.1016\/j.canlet.2013.04.012_b0045","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","article-title":"Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo","volume":"10","author":"Hu","year":"2010","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.canlet.2013.04.012_b0050","article-title":"The expression and significance of EZH2 in ovarian cancer tissues","author":"Yizhong","year":"2009","journal-title":"Modern Preven. Med."},{"key":"10.1016\/j.canlet.2013.04.012_b0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1158\/1535-7163.MCT-10-0788","article-title":"Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2","volume":"10","author":"Rizzo","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.canlet.2013.04.012_b0060","first-page":"567","article-title":"Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review)","volume":"16","author":"Aunoble","year":"2000","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2013.04.012_b0065","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1038\/onc.2008.333","article-title":"Repression of E-cadherin by the polycomb group protein EZH2 in cancer","volume":"27","author":"Cao","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.04.012_b0070","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1158\/1078-0432.CCR-08-1013","article-title":"Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2","volume":"14","author":"Ougolkov","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0075","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/j.1349-7006.2010.01836.x","article-title":"EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo","volume":"102","author":"Guo","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2013.04.012_b0080","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.canlet.2005.10.010","article-title":"Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines","volume":"241","author":"Imura","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2013.04.012_b0085","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/gyno.2000.5748","article-title":"P21 (WAF1\/CIP1) protein expression is associated with prolonged survival but not with p53 expression in epithelial ovarian carcinoma","volume":"77","author":"Schmider","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2013.04.012_b0090","first-page":"1169","article-title":"WAF1\/CIP1 is induced in p53-mediated G1 arrest and apoptosis","volume":"54","author":"el-Deiry","year":"1994","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0095","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S0140-6736(96)90163-4","article-title":"High hopes for p21 in cancer treatment","volume":"347","author":"Finkel","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2013.04.012_b0100","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.1073\/pnas.90.11.4961","article-title":"p53 gene mutations and protein accumulation in human ovarian cancer","volume":"90","author":"Kupryja czyk","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.canlet.2013.04.012_b0105","doi-asserted-by":"crossref","first-page":"5759","DOI":"10.1038\/sj.onc.1207706","article-title":"Activated p53 suppresses the histone methyltransferase EZH2 gene","volume":"23","author":"Tang","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2013.04.012_b0110","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.1471-0528.1989.tb03341.x","article-title":"Revised FIGO staging for gynaecological cancer","volume":"96","author":"Shepherd","year":"2005","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"10.1016\/j.canlet.2013.04.012_b0115","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.canlet.2013.04.012_b0120","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5","article-title":"Molecular effects of paclitaxel: myths and reality (a critical review)","volume":"83","author":"Blagosklonny","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2013.04.012_b0125","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","article-title":"Regulation of tumor angiogenesis by EZH2","volume":"18","author":"Lu","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2013.04.012_b0130","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/rmv.407","article-title":"RNA interference: on the road to an alternate therapeutic strategy!","volume":"13","author":"Dave","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.canlet.2013.04.012_b0135","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tcb.2005.08.003","article-title":"The Ezh2 methyltransferase complex: actin up in the cytosol","volume":"15","author":"Nolz","year":"2005","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.canlet.2013.04.012_b0140","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","article-title":"The polycomb group protein EZH2 is involved in progression of prostate cancer","volume":"419","author":"Varambally","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2013.04.012_b0145","first-page":"4499","article-title":"Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease","volume":"62","author":"LaTulippe","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0150","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.mrfmmm.2008.07.010","article-title":"Roles of the EZH2 histone methyltransferase in cancer epigenetics","volume":"647","author":"Simon","year":"2008","journal-title":"Mutat. Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0155","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.humpath.2010.03.004","article-title":"Implications of enhancer of zeste homologue 2 expression in pancreatic ductal adenocarcinoma","volume":"41","author":"Toll","year":"2010","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.canlet.2013.04.012_b0160","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canlet.2013.04.012_b0165","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/bjc.1997.38","article-title":"P53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study","volume":"75","author":"Buttitta","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2013.04.012_b0170","first-page":"2128","article-title":"P53 mutation is a common genetic event in ovarian carcinoma","volume":"53","author":"Milner","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0175","first-page":"702","article-title":"Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness","volume":"145","author":"Hsiao","year":"1994","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2013.04.012_b0180","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1158\/1940-6207.CAPR-11-0414","article-title":"ALDH1A1 Is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approaches","volume":"5","author":"Li","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0185","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.1007\/s11095-011-0547-x","article-title":"MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21 waf1\/cip1","volume":"28","author":"Semaan","year":"2011","journal-title":"Pharm. Res."},{"key":"10.1016\/j.canlet.2013.04.012_b0190","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","article-title":"Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer","volume":"322","author":"Varambally","year":"2008","journal-title":"Science"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513003327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383513003327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T17:23:35Z","timestamp":1539710615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383513003327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,8]]}},"alternative-id":["S0304383513003327"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2013.04.012","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21waf1\/cip1 and by inhibiting mutant p53","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2013.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}